India’s
Cipla to Invest £100m in UK R&D
Cipla Limited, a global
healthcare company, announced in collaboration with the UK Government, its
intention to make investments of up to £100 million in its UK subsidiary over
the next few years.
Said The Right Honourable
George Osborne, chancellor of the Exchequer, Her Majesty’s Government of the
United Kingdom: “I am happy to be able to announce that Indian pharmaceutical
company Cipla will invest up to £100 million in the UK. The investment will
fund the launch of a range of drugs in the areas of respiratory, oncology and
antiretroviral medicines as well as research and development, clinical trials
and further expansion internationally and in the UK.
Cipla is one of India's
leading pharmaceutical firms and this decision shows the UK's international
strength and attractiveness in this sector as well as its growing importance in
Cipla’s long term strategy" said the Chancellor
“On the occasion of the
66th anniversary of the British National Health Service (NHS) Cipla believes
that, by providing high quality affordable medicines for patients, it can
contribute cost effective solutions for the NHS. We are very pleased to be
making this investment in the UK. We were impressed with the pro-active support
and engagement that the UK Government and its various ministries showed in
attracting Cipla to choose the UK as a key hub in our global footprint” said
Rajesh Garg, global chief financial O\officer and member of the board of Cipla.
No comments:
Post a Comment